Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, ESR1 oncogenic variants, HER2-negative status confers therapeutic sensitivity to Imlunestrant in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Food and Drug Administration:
INLURIYO is an estrogen receptor antagonist indicated for treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.